Marín Córdova Norma Edith, Yan-Quiroz Edgar Fermín, Díaz Plasencia Juan, Churango Barreto Katherine, Calvanapon Prado Pamela, Salazar Abad Sarita
Universidad Privada Antenor Orrego. Trujillo, Perú.
Universidad Privada Antenor Orrego. Trujillo, Perú; Servicio de Cirugía Oncológica, Hospital de Alta Complejidad EsSalud Virgen de la Puerta. Trujillo, Perú.
Rev Gastroenterol Peru. 2017 Jul-Sep;37(3):217-224.
Determine the prognostic significance of metastatic lymph node ratio in 5-year survival of patients after curative distal gastrectomy for advanced gastric carcinoma.
This study survival analysis, prospective, observational, longitudinal, analyzed data from 68 patients with resectable advanced gastric adenocarcinoma treated at the Regional Institute of Neoplastic Disease Luis Pinillos Ganoza during the period 2008-2013.
The number of metastatic lymph nodes ranged from 0-29 (mean, 3.9±5.8) and the number of resected lymph nodes understood ranges from 13 to 66 (mean 35.34±12.60). There was no significant correlation between the number of metastatic lymph nodes and number of resected lymph nodes (r=0.208, p=0.089). Survival of the total number at 5 years was 55.9%, with a median survival of 44.11±3.38 months According to regional nodal status (N) of the 7th edition of the UICC, patients with N0 (n=27), pN1 (n=12), pN2 (n=17) and pN3 (n=12) showed survival rates at 5 years of 77.2%, 27.2%, 46.3% and 40% respectively (p=0.005). Patients were stratified into NR0 (reason 0%), NR1 (ratio 1-59%) and NR2 (ratio >60%). Their survival rates at 5 years were 77.2%, 40.9% and 33.3% respectively (p=0.013).
The metastatic lymph node ratio is a predictor system actuarial survival at 5 years compared consistent with regional nodal status (N) classification system of the International Union Against Cancer.
确定转移性淋巴结比率对晚期胃癌根治性远端胃切除术后患者5年生存率的预后意义。
本研究为生存分析，前瞻性、观察性、纵向研究，分析了2008年至2013年期间在路易斯·皮尼洛斯·加诺萨肿瘤病地区研究所接受治疗的68例可切除晚期胃腺癌患者的数据。
转移性淋巴结数量为0 - 29个（平均3.9±5.8个），切除的淋巴结数量范围为13至66个（平均35.34±12.60个）。转移性淋巴结数量与切除的淋巴结数量之间无显著相关性（r = 0.208，p = 0.089）。5年时总生存率为55.9%，中位生存期为44.11±3.38个月。根据国际抗癌联盟第7版的区域淋巴结状态（N），N0（n = 27）、pN1（n = 12）、pN2（n = 17）和pN3（n = 12）的患者5年生存率分别为77.2%、27.2%、46.3%和40%（p = 0.005）。患者被分为NR0（比率0%）、NR1（比率1 - 59%）和NR2（比率>60%）。他们5年的生存率分别为77.2%、40.9%和33.3%（p = 0.013）。
与国际抗癌联盟的区域淋巴结状态（N）分类系统相比，转移性淋巴结比率是5年精算生存率的预测指标体系。
